Maxis Clinical Sciences
Private Company
Funding information not available
Overview
Founded in 2018 and headquartered in London, Maxis Clinical Sciences (MCS) operates as a strategic advisory and services firm at the intersection of clinical research and digital health. The company provides integrated solutions centered on real-world evidence (RWE), data standardization (e.g., OMOP CDM), and AI to help pharma and biotech clients enhance clinical trial efficiency, demonstrate value, and personalize patient care. With a team of over 300 industry experts and a claimed track record of supporting 3,000+ clinical trials, MCS positions itself as a specialized partner for accelerating evidence generation and navigating the complexities of modern drug development.
Technology Platform
Integrated suite of data and AI solutions centered on Real-World Evidence (RWE) generation, including expertise in the OMOP Common Data Model (CDM) for data standardization, clinical trial tokenization for data integration, health economic modeling, and advisory on AI/GenAI adoption in pharma.
Opportunities
Risk Factors
Competitive Landscape
MCS competes in a fragmented market with large, full-service Contract Research Organizations (CROs) like IQVIA and Parexel, as well as numerous other boutique clinical and RWE consulting firms. Its differentiation is based on deep domain expertise, a strategic advisory focus, and niche technical capabilities in data standardization and AI.